Literature DB >> 27866120

Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS).

Jean-Pascal Lefaucheur1, Andrea Antal2, Samar S Ayache3, David H Benninger4, Jérôme Brunelin5, Filippo Cogiamanian6, Maria Cotelli7, Dirk De Ridder8, Roberta Ferrucci6, Berthold Langguth9, Paola Marangolo10, Veit Mylius11, Michael A Nitsche12, Frank Padberg13, Ulrich Palm13, Emmanuel Poulet14, Alberto Priori15, Simone Rossi16, Martin Schecklmann9, Sven Vanneste17, Ulf Ziemann18, Luis Garcia-Larrea19, Walter Paulus2.   

Abstract

A group of European experts was commissioned by the European Chapter of the International Federation of Clinical Neurophysiology to gather knowledge about the state of the art of the therapeutic use of transcranial direct current stimulation (tDCS) from studies published up until September 2016, regarding pain, Parkinson's disease, other movement disorders, motor stroke, poststroke aphasia, multiple sclerosis, epilepsy, consciousness disorders, Alzheimer's disease, tinnitus, depression, schizophrenia, and craving/addiction. The evidence-based analysis included only studies based on repeated tDCS sessions with sham tDCS control procedure; 25 patients or more having received active treatment was required for Class I, while a lower number of 10-24 patients was accepted for Class II studies. Current evidence does not allow making any recommendation of Level A (definite efficacy) for any indication. Level B recommendation (probable efficacy) is proposed for: (i) anodal tDCS of the left primary motor cortex (M1) (with right orbitofrontal cathode) in fibromyalgia; (ii) anodal tDCS of the left dorsolateral prefrontal cortex (DLPFC) (with right orbitofrontal cathode) in major depressive episode without drug resistance; (iii) anodal tDCS of the right DLPFC (with left DLPFC cathode) in addiction/craving. Level C recommendation (possible efficacy) is proposed for anodal tDCS of the left M1 (or contralateral to pain side, with right orbitofrontal cathode) in chronic lower limb neuropathic pain secondary to spinal cord lesion. Conversely, Level B recommendation (probable inefficacy) is conferred on the absence of clinical effects of: (i) anodal tDCS of the left temporal cortex (with right orbitofrontal cathode) in tinnitus; (ii) anodal tDCS of the left DLPFC (with right orbitofrontal cathode) in drug-resistant major depressive episode. It remains to be clarified whether the probable or possible therapeutic effects of tDCS are clinically meaningful and how to optimally perform tDCS in a therapeutic setting. In addition, the easy management and low cost of tDCS devices allow at home use by the patient, but this might raise ethical and legal concerns with regard to potential misuse or overuse. We must be careful to avoid inappropriate applications of this technique by ensuring rigorous training of the professionals and education of the patients.
Copyright © 2016 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cortex; Indication; Neurological disease; Neuromodulation; Noninvasive brain stimulation; Psychiatric disease; Treatment; tDCS

Mesh:

Year:  2016        PMID: 27866120     DOI: 10.1016/j.clinph.2016.10.087

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  323 in total

Review 1.  Idiopathic Hypersomnia.

Authors:  Lynn Marie Trotti
Journal:  Sleep Med Clin       Date:  2017-06-16

2.  Transcranial direct current stimulation of default mode network parietal nodes decreases negative mind-wandering about the past.

Authors:  Tina Chou; Jill M Hooley; Joan A Camprodon
Journal:  Cognit Ther Res       Date:  2019-09-28

Review 3.  Developing an optimized strategy with transcranial direct current stimulation to enhance the endogenous pain control system in fibromyalgia.

Authors:  Dante Duarte; Luis Eduardo Coutinho Castelo-Branco; Elif Uygur Kucukseymen; Felipe Fregni
Journal:  Expert Rev Med Devices       Date:  2018-12-03       Impact factor: 3.166

4.  Magnetic Strategies for Nervous System Control.

Authors:  Michael G Christiansen; Alexander W Senko; Polina Anikeeva
Journal:  Annu Rev Neurosci       Date:  2019-04-02       Impact factor: 12.449

Review 5.  Transcranial Direct Current Stimulation as a Therapeutic Tool for Chronic Pain.

Authors:  Camila Bonin Pinto; Beatriz Teixeira Costa; Dante Duarte; Felipe Fregni
Journal:  J ECT       Date:  2018-09       Impact factor: 3.635

Review 6.  Motor Cortex Stimulation for Deafferentation Pain.

Authors:  Ahmed E Hussein; Darian R Esfahani; Galina I Moisak; Jamil A Rzaev; Konstantin V Slavin
Journal:  Curr Pain Headache Rep       Date:  2018-05-23

Review 7.  New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease.

Authors:  Giacomo Grassi; Giovanni Albani; Federica Terenzi; Lorenzo Razzolini; Silvia Ramat
Journal:  Neurol Sci       Date:  2021-04-14       Impact factor: 3.307

Review 8.  Spinal control of motor outputs by intrinsic and externally induced electric field potentials.

Authors:  Elzbieta Jankowska
Journal:  J Neurophysiol       Date:  2017-05-24       Impact factor: 2.714

9.  Transcranial Alternating Current Stimulation of the Primary Motor Cortex after Skill Acquisition Improves Motor Memory Retention in Humans: A Double-Blinded Sham-Controlled Study.

Authors:  Tomofumi Yamaguchi; Christian Svane; Christian Riis Forman; Mikkel Malling Beck; Svend Sparre Geertsen; Jesper Lundbye-Jensen; Jens Bo Nielsen
Journal:  Cereb Cortex Commun       Date:  2020-08-06

10.  Efficacy of transcranial direct current stimulation over primary motor cortex (anode) and contralateral supraorbital area (cathode) on clinical pain severity and mobility performance in persons with knee osteoarthritis: An experimenter- and participant-blinded, randomized, sham-controlled pilot clinical study.

Authors:  Hyochol Ahn; Adam J Woods; Mark E Kunik; Abhishek Bhattacharjee; Zhiguo Chen; Eunyoung Choi; Roger B Fillingim
Journal:  Brain Stimul       Date:  2017-05-19       Impact factor: 8.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.